Cover Image
市場調查報告書

曲弓熱(屈公熱):開發平台分析

Chikungunya Fever - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 251540
出版日期 內容資訊 英文 101 Pages
訂單完成後即時交付
價格
Back to Top
曲弓熱(屈公熱):開發平台分析 Chikungunya Fever - Pipeline Review, H2 2016
出版日期: 2016年10月12日 內容資訊: 英文 101 Pages
簡介

曲弓熱(屈公熱)是由埃及斑蚊虰咬而傳染給人類的病毒性疾病。病原體屈公病毒(CHIKV)是Togaviridae科Alphavirus屬的病毒。主要症狀有激烈的關節痛,及關節部的腫脹·僵直化、肌肉痛、頭痛、倦怠感、噁心·嘔吐、皮疹·發燒等。主要治療藥為非甾體抗炎藥物(NSAID)等。

本報告提供全球各國治療曲弓熱(屈公熱)用的開發中產品之開發情形相關分析,提供產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

曲弓熱(屈公熱)概要

治療藥的開發

  • 曲弓熱(屈公熱)開發中產品:概要
  • 曲弓熱(屈公熱)開發中產品:比較分析

各企業開發中的曲弓熱(屈公熱)治療藥

大學/研究機關研究中的曲弓熱(屈公熱)治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品
  • 不明確的階段有的產品

曲弓熱(屈公熱)治療藥:開發中的產品一覽(各企業)

曲弓熱(屈公熱)治療藥:研究中的產品一覽(大學/研究機關別)

曲弓熱(屈公熱)治療藥的開發企業

  • Abivax S.A.
  • Arbovax, Inc.
  • Arno Therapeutics, Inc.
  • Bharat Biotech International Limited
  • Etubics Corporation
  • Indian Immunologicals Limited
  • Inovio Pharmaceuticals, Inc.
  • Integral Molecular, Inc.
  • Merck & Co., Inc.
  • Nanotherapeutics, Inc.
  • PaxVax
  • Profectus BioSciences, Inc.
  • 武田藥品工業
  • Themis Bioscience GmbH

曲弓熱(屈公熱):治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • ABX-309
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • AR-12
  • 曲弓熱(屈公熱)疫苗
  • DEF-201
  • IMCKV-063
  • 曲弓熱(屈公熱)的單株抗體
  • 曲弓熱(屈公熱)CHIKV E2抑制用單株抗體
  • 曲弓熱(屈公熱)病毒性E1/E2蛋白質抑制用單株抗體
  • MV-CHIK
  • 曲弓熱(屈公熱) NS2及NS3 阻礙小分子
  • 曲弓熱(屈公熱)感染疾病病毒RNA阻礙小分子

曲弓熱(屈公熱)治療藥:開發中產品的最新趨勢

曲弓熱(屈公熱)治療藥:開發暫停的產品

曲弓熱(屈公熱)相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8524IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H2 2016, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 19 and 3 respectively for Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 6 molecules, respectively for Chikungunya Fever.

Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Chikungunya Fever Overview
  • Therapeutics Development
    • Pipeline Products for Chikungunya Fever - Overview
    • Pipeline Products for Chikungunya Fever - Comparative Analysis
  • Chikungunya Fever - Therapeutics under Development by Companies
  • Chikungunya Fever - Therapeutics under Investigation by Universities/Institutes
  • Chikungunya Fever - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Chikungunya Fever - Products under Development by Companies
  • Chikungunya Fever - Products under Investigation by Universities/Institutes
  • Chikungunya Fever - Companies Involved in Therapeutics Development
    • Abivax S.A.
    • Arbovax, Inc.
    • Arno Therapeutics, Inc.
    • Bharat Biotech International Limited
    • Ennaid Therapeutics, LLC
    • Etubics Corporation
    • Hawaii Biotech, Inc.
    • HSRx Group
    • Indian Immunologicals Limited
    • Inovio Pharmaceuticals, Inc.
    • Integral Molecular, Inc.
    • Integrated BioTherapeutics, Inc.
    • Merck & Co., Inc.
    • Nanotherapeutics, Inc.
    • Profectus BioSciences, Inc.
    • Takeda Pharmaceutical Company Limited
    • Themis Bioscience GmbH
    • Valneva SE
    • Vaxart, Inc.
  • Chikungunya Fever - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ABX-1089 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABX-1091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ABX-311 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antibody for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AR-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya (viral like particles) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • chikungunya vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DEF-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSRx-431 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMCKV-063 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Chikungunya and Ross River Virus Fever - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MV-CHIK - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptides for Infectious Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides for Chikungunya - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Tatbeclin-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Chikungunya Fever - Dormant Projects
  • Chikungunya Fever - Product Development Milestones
    • Featured News & Press Releases
      • Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine
      • Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2
      • Mar 22, 2016: Inovio's DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study
      • Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs
      • Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
      • Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus
      • Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1
      • Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful
      • Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate
      • Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine
      • Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models
      • Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Chikungunya Fever, H2 2016
  • Number of Products under Development for Chikungunya Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Chikungunya Fever - Pipeline by Abivax S.A., H2 2016
  • Chikungunya Fever - Pipeline by Arbovax, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Arno Therapeutics, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Bharat Biotech International Limited, H2 2016
  • Chikungunya Fever - Pipeline by Ennaid Therapeutics, LLC, H2 2016
  • Chikungunya Fever - Pipeline by Etubics Corporation, H2 2016
  • Chikungunya Fever - Pipeline by Hawaii Biotech, Inc., H2 2016
  • Chikungunya Fever - Pipeline by HSRx Group, H2 2016
  • Chikungunya Fever - Pipeline by Indian Immunologicals Limited, H2 2016
  • Chikungunya Fever - Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Integral Molecular, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Merck & Co., Inc., H2 2016
  • Chikungunya Fever - Pipeline by Nanotherapeutics, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Profectus BioSciences, Inc., H2 2016
  • Chikungunya Fever - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Chikungunya Fever - Pipeline by Themis Bioscience GmbH, H2 2016
  • Chikungunya Fever - Pipeline by Valneva SE, H2 2016
  • Chikungunya Fever - Pipeline by Vaxart, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Chikungunya Fever - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Chikungunya Fever, H2 2016
  • Number of Products under Development for Chikungunya Fever - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top